Q4 2019 Earnings Call
On life will be place unless an only mode throughout the conference.
After the speakers presentation, there will be a question and answer period.
I like to turn the conference over to Mr. Michael rarely director of Investor Relations for F.M.C. Corporation, you May now begin.
Thank you and good morning, everyone welcomed F.M.C. corporations fourth quarter earnings call.
Joining me today are appear Brondeau, Chairman and Chief Executive Officer, Mark Douglas, President and C.L. Act, and Andrew Sanfer Executive Vice President and Chief Financial Officer.
Pierre overview, F.M.C. fourth quarter and pull your performance.
Then Andrew will provide an overview of select financial results and then Mark will discuss the company's 2020 outlook.
S. Your questions.
The slide presentation that accompanies our results along with our earnings release in our 2020 outlook statement are available on our website and the prepared remarks from today's discussion will be made him available after the call.
Finally, let me remind you that today's presentation and discussion will include forward looking statements that are subject to various resend uncertainties concerning specific factors, including but not limited to those factors identified in earnings earnings release and in our problems with the S.P.C.
Information presented represents our best judgment based on today's understanding.
The results May vary based upon these recipes uncertainties.
Today's discussion in the sporting materials will include references to adjust to the U.P.S. adjusted EBITDA adjusted cash from operations and free cash flow all of which are now I guess financial measures. Please note that earning shall mean adjusted earnings and eat it actually I mean, adjusted Aber Das for all income statement references.
Reconciliation in definition to these terms as well as the other night financial terms to which we may refer during today's conference call are provided on our website.
What's that I will now trying to call over to <unk>.
Thank you Michael and good morning, everyone.
If it season strong financial performance continued into fourth quarter.
Cutting an accent on here for the company.
That's a formants was much like volume growth across all regions and once again highlighted the benefit of the balance geographic exposure the string Oh pulled full you and the impacts on new product launches.
Turning to say to me.
She reported $1.2 billion in fourth quarter revenue, which we flick. So you don't movie you increase or 9% on the reporting basis and they live in per cent organic growth excluding <unk>.
These increase was driven by double digits organic growth in Argentina, Canada.
Russia, India, China, Indonesia implications.
Has witnessed price increases across the whole regions, except North America.
That's just that's company yeah.
Well $320 million, an increase of 17% compared to the prior year period in the <unk> over again.
<unk>, we're about 27 per cent, that's 180 basis points year over year.
Right $28 million in combined Headwins from raw much at all costs cherries and ethics <unk>.
I just said he P.S. was 1.7 seeks <unk>.
In the quarter, so an increase of 21%.
Excuse me cast queue for 2018.
Yeah, well the your performance was even an elderly man 34 cents increase.
<unk>.
And the benefits of reduced sheer account, partially upset by higher interest expense.
Compared to a most <unk> since guidance I, just said, yes, well. It's also much how you do do very strong will be original performance.
Hi, a volume and surely cross cultural drove seven cents Oh performance versus again.
Well the much lower than focusing sex made in the quarter resulted in 21 sense of the beach versus ghettos.
Moving now to slide for.
Q full really you grew by 7% she's probably here.
<unk> volume contributing 11% growth well said, partially maybe a two per cent headwind from effects.
Overruled price was flat has increased rebates in North America, Oh said strong pricing in the other three regions.
Given to start well just sell them Hemisphere Caesar and that's in America made up over 40% over a fourth quarter revenue.
Sales.
<unk>.
Good, 10% euros, or you or 13% organ equally.
Even they very strong growth in Argentina, and single digit growth <unk> and makes you cool.
<unk> posted significantly higher volumes for a free imagine <unk>.
We are very pleased with the reason. These results you know just here as you may recall, we talked about the significant changes we made it to improve <unk> you know since you know, which I'm now <unk> on their expectations.
Oh, that's forecasted fully before quarter is very strong double digit growth.
He'll girls sued in Q4, but continued didn't either increased volume.
Channel inventories, although proto in Brazil remain at normal levels for these points of the season and not well under control heading into 2020.
In North America revenue increase 10 per cent your career driven by strong demand for next appearing said cultural in specialty crops growth of those X. me a combination in 60 sat in front decide for infer what <unk> and our new Lucent too.
<unk>.
So it'd be set sales in Canada, we're also strong.
Overruled volume was above what was expected into quarter, resulting in higher than forecasting relate.
These we base our accounted for on.
Price pressing line, which books that price increases in other regions.
We continue to closely monitor channel you centuries of the products in the U.S. as we entered into this spring.
To ensure that reduction of those channel inventories only your over your Bayes, We <unk> list all the all three cheap pre emergence army side.
Do the channel <unk> or 2019, then we did in the same period.
Twin Jean 18.
Yeah.
Very strong fourth quarter performance with a rhythm you increase of 9% and 10 per cent organic growth year over year, you know another wise down market.
Yeah, China, Indonesia, and stuck Easton, all recorded that'll digit growth rate, even by instinct decided volumes.
Following a very strong cute you wouldn't use friesz in yeah, deaver over 20% revenue growth in q. for even by rice, and sugar cane up <unk> and new product launches.
China strong revenue growth, whereas even they damn I demand in phones, you said sales in features and vegetable applications.
Any any any.
She has grew 5% of the rule as friends UK, Russia, Italian Romania, all posted double digit year over year growth.
<unk> Oh can you grow up in the region was 7%.
Even lousy by sealed in France, and Russia, which more than upset difficult drought conditions that in fact, it's year old planting in central and Eastern Europe.
Turning to the fourth quarter.
On slide five.
You see the $75 million volume contribution, which came from all regions and reached draw the euro over your growth.
We let him do relate to it again, it's both volume and cost management.
Led to this trone Elwood performance.
Oh say six.
Full year revenue was $4.6 million.
Increase of 8% compared to the prayer.
<unk>, well, 3% needs to be presents 11% organic growth.
Full year, adjusted G.P.S. increase the 85 cents year over year or 16%.
Even loudly, but you'd be that girls and the Benny seat Oh sharing approaches.
Oh said seven.
You can see that if him she growth for 2019.
We are well ahead of the crop protection market in every region.
These person dangerous.
<unk> Oh in you as that of terms.
Despite the extreme winter.
And trade challenges into Europe, a fool, you <unk>, where a 3% which was ahead of the forecast in 900 misuse points for the end of the market.
It seems he fool you don't sales in Latin America grew 19% she sounded veggies qualitative the market and 23% on an equally.
Any any <unk> grew 4% into your which was 700, that's just point to the head of the market in 10% of any coding.
If in C. revenue growth in Asia, or three per cent only reported business 800, this points to add on the market and 8% organ equally excluding ethics headwinds across many currencies.
<unk>.
<unk> eight per cent in 2019 in U.S. none of terms.
Just a flat global market.
We believe.
Outperformance every region, whereas knew the strength of a portfolio, a crumb balance and a strong commercial commercial prisons around the world.
Moving to slide eight.
Well, you can see or a fool <unk> and ruin your drivers.
Volume, what's the main driver of revenue growth.
<unk> price increase sales by 3%.
Almost 20% of these students Ruben you grow came from 2019 product launches.
<unk> index, which we calculate as improve portion of total revenue coming from products in should use in the last five years was roughly 10% or two of those hills.
The <unk> grew into <unk> in 2019, and the rest of the portfolio grew into need single digits.
On a cue to running school, we outlined plans to profit W. group or them at franchise well beyond the <unk> of keep buttons and all the way through the interviews Decatur via engagement of third parties.
We indicated we hadn't place Oh, we're negotiating 15 search commercial agreements.
Six months later.
We have expended the number of agreements to cover for global partnership.
And 41, Sip parade local company agreements covering 11 countries.
The number on these new agreements are active and commercial sales are occurring.
We will continue to expand the franchise through more on these commercial agreements.
These upon the sheets are important and in most cases.
L.S. to access markets, we are not sailing into today.
They are <unk> extension for the commercial rich.
2019, just you'd be that on $1.22 billion was up 10% you're over here.
Despite $228 million combine headwins from higher costs and effects.
Revenue and the he'd be that growth rate in 2019, a book above the high end of the <unk> targets. We provided in December 20 any teaching.
<unk> turn each over to Andrew.
Thanks there.
I'll start this morning with a few highlights from the income statement, then moved to the balance sheet cash flow and share account.
Also get a quick update on progress and implementing our new S.I.P.S. 400 system.
Interest expense for for your 2019 was $158.5 million $3.5 million above our most recent guidance, primarily due to higher than forecasted foreign debt and commercial paper balances.
For 2020, we anticipate interest expense between 160 and $170 million.
Increase largely attributable to hire foreign debt balances, particularly where we utilize local bar on is to reduce currency exposures.
Are effective tax rate on adjusted earnings for the full year 2019 was 11.6% 290 basis points lower than anticipated.
<unk> corporate structure, particularly the principal operating companies that were created as part of the pot transaction at 2017.
Provide F.M.C., where they structurally low tax rate.
With this structure profit outside the United States is taxed at lower statutory are negotiated tax rates than profit in the U.S.
Resulting in a weighted average tax rate well below the U.S. statutory rape.
To be clear even at this lower overall rate F.M.C. does encourage significant amount of U.S. hacks on the non U.S. profits under the global intangible low tax income or guilty for it.
The structural elements to drive are low overall effect of tax rate are highly sustainable and we expect a low rate for many years to calm.
However, the effective tax rate in any period is sensitive to swings and profitability between geography.
Most notably the amount of profit earned in the U.S.
Significant contributors to are lower than expected tax rate and 2019 or lower than for forecasting earnings in the U.S. due to the factors in our North America business Pierre mentioned earlier combined with the stronger than forecasted earnings that flowed through our principal operating companies outside of the U.S.
Looking ahead to 2020, we expect a full your tax rate of 12.5% to 14.5% based on our current estimates of taxable earnings by geography.
At year end gross debt was $3.3 billion down roughly $300 million from the end of the third quarter.
Surplus cash on the balance sheet at year end wasn't access at $225 million to the timing of receipt of end of your payments, which prevented us from using this cash to further pay down that prior to your at <unk>.
Considering the surplus cash it in your N. gross data trailing 12 month, even die with just under our 2.5 times target.
We rent we remain committed to solid investment Grad credit metrics and expect for your average leverage to be in line with this commitment in 2020.
Moving to slide nine and cash flow.
Free cash flow for 2020 was $302 million.
$172 million from the prior year.
Higher adjusted cash from operations driven by higher either died lower use of cash for working capital and lower legacy and transformation spending more than off that an increase in capital additions compared to the prior year.
We are pleased with the improvements made and trade working capital trade working capital as a percentage of sales at year end decrease 210 basis points to 32.5% and 2019.
Free cash conversion relative to adjusted net earnings what's 38% for full year 2019 more than twice the prior year on a like for like batches with free cash flow growing 10 times as fast as artists.
However, free cash flow came in below the low end of our outlook range of $375 million to $475 million.
Two factors largely contributed to this.
The first was much lower than expected collection of refunds a value added similar taxes, especially in India.
The delays are driven primarily by the complexities of operating in multiple S.I.P. and non S.A.P. systems around the world.
The second factor was delayed collections in Pakistan in Indonesia.
Weather conditions impacted grower liquidity late in the fourth quarter.
Both factors are execution related and will reverse we fully expect to collect this cash and 2020.
In the absence of these two factors are free cash flow for 2019 would've been solidly in our guidance ranch with free cash conversion of roughly 50 per cent on higher than guided on it.
We know we have more to do to continue to improve free cash flow.
Moving to a single instance of S.A.P.S. four on it this year will give it a different level of visibility across our entire business more provide us with the state of the our tools to continue to drive improvement and working cap on cash flow.
Looking ahead to 2020, we're forecasting free cash flow of $425 million to $525 million with free cash conversion from adjusted earnings of 55% at the mid point of our guys ranges.
We continue to believe we can drive free cash conversion substantially higher over the coming two to three years.
Finalize R.S.I.P. implementation ending the period of high cash spending on transformation activity and as we dry further improvement and working capital performance.
We repurchased over 4.7 million F.M.C. shares in 2019 at an average price at $84 and 73 sets.
Included $100 million and repurchases completed in the fourth quarter for a total of $400 million of repurchases in the air.
Considering the $210 million paid dividends M.C. returned over $600 million and catch the shareholders and 2019.
We are committed to returning excess cash the shareholders consistent with our long range plan.
Further evidence of this commitment as a 10% increase in our quarterly cash dividend announced in December.
We intend to purchase between 400 and $500 million of F. from C. shares in 2020.
In light of the seasonal working capital build and the first quarter and ongoing product line acquisition discussions, we do not expect to make any meaningful share repurchase isn't the first quarter.
But fully intend to remain a regular purchaser shares through the rest of the year.
Before turning to call over Tomorrow, Let me also get a quick update on progress in implementing our new essays he asked for Hannah U.R.P. system.
We successfully closed full year 2019, with roughly 20% of the company on the new system and are already seeing many benefits.
Today, we are going alive across the acquired business, which represents roughly 40% of and see.
This will allow us to exit the transition services agreement at the end of this month delivering annual cost savings of $20 million, which are incorporated in our earnings guidance for 2020.
And with that I'll turn the call over to Mark.
Thank you Andrew moving to slide 10, and the review of our full year 2020, and Q1 earnings outlook.
We expect full year adjusted earnings of $6 45 to $6 70, pet diluted shit, representing an 8% increase at that point.
This outlook three P.S. does not include the impact of Sherry purchases in 20 220.
Revenue is expected to be in the range of $4.8 billion to $4.95 billion.
Representing 6% growth at the midpoint and 7% organic growth compared to 2019.
Total completely adjusted EBITDA is forecast it to the in the range of $1.3 billion to $1.34 billion, reflecting 8% you ever get growth at that point.
Looking at the first quota, we expect adjusted earnings per diluted share to being the range of $1.76 to $1.86, representing an increase of 5% at the midpoint.
Q1, 2019, and assuming a check out approximately 100 with that too 1 million.
We focus Q1 revenue to be in the range at $1.23 billion to $1.27 billion.
Presenting 5% growth at the midpoint compared to the first quarter of 2090.
Adjusted EBITDA is focused it to be in the range of $346 million to $366 million, representing a full percent increase at the midpoint versus the price period.
Sending now two hour Twentytwenty, Eva Dot bridge on slide 11.
I'll read the dog growth is expected to be driven by volume gangs and continued price increases.
We should know that we are also expecting to invest about $40 million mall on our end date in twentytwenty.
This increase is driven by continued success in moving molecules into development from discovery in 2019.
Total r. and D. spend should be approximately 70% of sales.
Six and a half the sense of sales in 2019.
As we continue to expand and progress 22, new active ingredients and eight new biologicals towards commercialization.
Paris will be hiring 20, 220, well raw material costs will not materially improve until the second half of Twentytwenty.
We will realize about $20 million in annual savings as we exit the transition service agreement this month.
Foreign exchange is also focused it'd be a headwind in twentytwenty as the U.S. dollars further strengthen versus t. currencies.
However, if you exclude the incremental $40 million in R. and D. spend a price increases will cover over 100% to be combined headwinds from costing effects.
I would also like the high like a revenue drivers.
We forecast Twentytwenty revenue growth of 6% overall and 7% organically.
Human is expected to contribute 5% growth, including about 1.5% from new products launched in Twentytwenty.
Pricing is expected to contribute 2% growth.
He's a slightly offset by a 1% headwind from foreign exchange.
One aspect of our portfolio management that we do not often highlights is the changing the makeup of our portfolio.
Is the case every it in Twentytwenty, we will have an adverse impacts from last registrations on molecules as well as decisions to exit some product lines.
This typically represents a drag of about 2%, although revenues and yet in 2019, we still grew volume 8%.
Least portfolio impacts are factored into our longtime revenue growth targets.
Sound product strategy of investing in an increasingly sustainable product portfolio.
Requires that we continually replace older chemistries with new more sustainable technologies.
As part of this effort.
The end of year 29 team F.M.C. has stopped selling oh top of your own formulations, including fewer than insecticide globally.
Moving to slide 12 will provide the key drivers for <unk> revenue growth in the first quarter.
First quarter performance will be driven by strong volume growth, including new product launches, which is expected to deliver about a third about total revenue growth in the quota.
<unk> launches include authority edge pre imagine how beside for soybeans in the U.S. I'm baffled Delta happy side for sales in Europe.
Pricing actions are expected to fully offset the F.X. headwinds at the revenue level.
Shifting to the global crop protection market.
We project the total market will grow in the low single digits in Twentytwenty on a U.S. dollar basis with each region also growing by low single digits.
We focus to Asia, we'll have the highest growth rate, assuming a partial rebound in Australia and more normalized weather conditions across the region.
In North America grow up is expected to come from recovery and acreage for row crops offset by a higher than normal channel inventory levels heading into the year.
In Latin America growth in soybeans, and corn are expected to lead the crop protection market in Brazil.
In any a growth will be driven by spring serial hub. Besides following the challenging winter serial CD.
<unk>.
Thank you Mark.
Companies owed performance in 2019 was the result, only very flexible and to jail supply chain limiting the impact of Rome material shortages and delivery of monkey, even technologies that oh for exceptional value growers around the world we strong.
We believe that are in this and you know discovery in development pipeline will continue to fuel long term grew up for the company.
In Twentytwenty, we will continue to effectively navigate through unexpected challenges that arise such as whether well macro economic developments.
And we'll deliver on the financial targets, we said I would for you today.
We believe twentytwenty log the third year neural than S.M.C. significant the old performs the Crow prediction markets income of revenue growth and you'd be them audience.
We expect her I would performance will be driven by broadbased geography growth launches Oh, new products and technologies in the continued expansion Hoover dam I'd franchise, as we gain more registration and labels as well as group yeah commercial partnerships.
I will now turn on the cold back to view parent or four questions.
Thank you very much for your attention.
If you would like to X. a question at this time. Please press Star then one.
On your telephone keypad. Please limit yourself to one question only if you have additional questions you can jump backing cue.
You can also read drag yourself from the Q. at any time by pressing the one zero command well pause for a moment to compile the key when a roster.
And our first question comes from a line of Adam <unk> with Goldman Sachs. Your line is open.
Hi, good morning, how are you.
Good morning, I I I was hoping that maybe to dig into the the guidance details a little bit and just think through.
The cost side and you give some color I heard remarks about our do you had about investments in our India and raw materials, but maybe just a little bit more color around the living pieces or.
Sure I'm I think if we look at the full year guidance, we see it you know many way the pattern similar to what we saw last year, but with a less pronounced had went from costs in F.X. on the cost side, you're exactly right. We are yeah. We have called out we're increasing our investment in R. and D. about $40 million you're on.
<unk> so of that $61 million that you see in cost increase for the full year on our bread on flight 11, Yeah about 40 of that is costs increase from Ross.
From R. and D. spending yeah. If you if you if you remove that we really do have you know we start to see the benefit of the pricing actions, we've taken over the past five quarters, where prices and mix ends up covering more than the cost and F.X.N. ones. Yeah. I do think we did see continued higher raw material costs anti conditions going into the second half.
Last year that as you know as they float or I mentor in the first half. This year will continue to be a bit of ahead, when and and the U.S. dollars continues to strengthen against the number of archey currencies. So we do still have some F.X. had when I will note that that that those headwinds are particularly heavy in the first half as we start looking towards the second.
In half, we start seeing much more favorable comparisons on costs and lessening F.S. impacts.
On the on the volume from to talk about girls jumping but.
Roughly three three big buckets, I would say <unk>.
We we do believe it's gonna be broad base, a geographical growth and it's going to be the in the low teams.
Think about the rest of the <unk> 2019, grinning at about a green got about 5% and and as in the in 19, we believe the product we will be launching into Twentytwenty will also bring about 2% group.
Right.
Okay. That's that's very helpful color and then just quickly on the cash flow conversion guidance, 55% just apart from the continued investments in any European transformation I mean, what would it what else would it take to get to that medium term target of a of 70 per cent as we think.
20 versus 20 122.
Yeah, let me lets them one thing and let me just take a beat the.
The trend from the 18 older way to 21 at a high level and then then maybe Andrew you can you can go into more detail into the 2019 2020 number.
You look back at twin T. 18, we had a conversion rates of 18%.
In 2019, we generated 300 million, there's a free cash flow, which we present a conversion rate of 37% know these 300 million. There's no load I should've been 400, meaning that are as we had at 100 million there <unk> purely execute.
<unk>.
Go to eyes of the bull on on a couple of issues.
But the normalize number we don't even around 400 million. Those we should you know about a 50 per cent Caucasian rate.
Looking into 2020 2020, I would characterize as you are the beach along the same line as a as 2019, we believe we're going to benefit from <unk>.
<unk>, 8% growth.
But from the cost 10 point, we were expecting about a year ago to be able to <unk> in the first quarter of 2020, but you know there there is no way around it. It's a three year program, it's going to cost $250 million. So we're gonna have to go all the way too trivial 20.
20, we've S.A.T. implementation costs. So we're going to have the same transformational cost as we did in 2019. So we believe.
Twentytwenty will be a conversion rates over about.
55% now you move into 2021, and that's when you still see if we go along the line of aside your plan for another 8% he'd be they increase but that's when the S.A.P. implementation transformation cost stuff to significantly lower.
And that's when just when you say effect, we expect to be around 70 per cent cash cash a conversion from from registered earnings. So that's a <unk> that's directional the how we're going to go from 37% in 2019 to about 70 per cent seen 2021.
Maybe Andrew you want to talk a bit more about 19 and 20 sure. Let me talk against the little more says on that on that bridge from 19 to 20 I think it's peer referenced you know, we we're I've, yeah about $300 million and free cash flow in 19 were guiding an increase an even dodd about $100 million.
Also be increasing the spending on <unk> about $10 million a year on year, and our legacy and transformation costs increase about $20 million year on year. The combination of those factors or leave it about 370, the net the net impact of the reversal of the two factors, we called out in them and the cash.
Shortfall this quarter and the impact of changing working capital on 2020 are the rest of the difference to the rest of our guidance ranch. It gets you up in that for 25 to 575. So it's important in that 2020 walk is pure mention yeah, we do not see a step down we actually see a slight increase and legacy and transformations.
We're on year, what about 100 to 125 of that being really transformation activity and the remainder being legacy expenses, yet that basically transformation being flat to slightly down to prior year in total with legacy going up slightly so again that next real big staffing cash conversion.
Into a more normalize level this year for our operating it on a working capital and then 2021, we see the stepped down from the end of the S.A.P. program in the end of the transformation spent.
And just to remind or please let me yourself to one question. If you have additional questions. Please jump back and kill the next question comes from the line of P.J. do you have a cart one city here line is open.
But to North America is that mostly they <unk> based on volume like a volume rebate or is that more of a competitive action.
And in what products is that occurred thank you.
Yeah P.J. <unk>.
Just a normal it's a normal process, which which happens.
Every year, we do this in seeing we we have rebates.
Which are indexed on the on volume and and that's it that's a normal process. There was no as specific changing in in the race or or anything of that kind. It was just a normal you are the only difference looking into whether <unk> Picheny North America.
We ended up so it'd be stronger in in the in the fourth quarter. Then we're expecting so when we have <unk> all of the reserves and and.
And rebates, we would have to be wind up having higher rebate to be to be paid to a customer's folder full year into be done in the fourth quarter. So we just we go to the little bit surprised by the strength of the market in the in the fourth quarter versus what we were expecting in that because.
Purely proportional to volume created a step up in rebates, we're not expecting.
And the next question comes from the line of Christopher Parkison Credit Suisse.
Airline is okay.
Thank you so you've got a solid job of evolving the portfolio for both the geographic and crop perspective, which I guess is you know kind of the key to enabling you to outgrow C.P.C. markets. However, you're still under weight fungicides and you know kind of overweight insecticides you know it seems like you're entering a lot of agreements regarding tech sharing in the die minds over the long term.
But how should we think about you know your total portfolio evolution as it pertains to further establishing your presence in fungicides and is it a coincidence that you mentioned you know product line acquisition discussions I nominate thank you.
Yeah of course, you're absolutely right, we all heavyweight insecticides I believe with the wells leader in insecticides. So we're not disappointed with that profile at all however, you're right. We do want to increase our participation in funky sides.
We were doing that in three ways first of all these <unk> portfolio, which is limited, but with very very interesting products, we launched a new product this year or 2019, the sentencing North America, it's going extremely well to be Frank I think if we'd have had more capacity, we to being able to sell them. All so there is the the notion of selling what we.
Today second to that is what we have you know a pipeline when you think about out discovering develop them pipeline. We currently have today five new fungus sides in L. pipeline.
Three of which have brand new modes of action not seen before so we know we have the longtime view, which is very strong from a.
From the fungus I perspective closer to home, we will be launching and 2021 a brand new.
<unk>.
We'll be launching that around the world that will also add to the growth rate as we go through sort of the second half of our plan and then third is how we acquire technologies or access to products around the world we are under active.
<unk> and in fact, some of the agreements that we have in place today for the dialogues allow has access to various fungus sides in different markets. So we pursuing pretty much every avenue, we know to really grow that find besides as fast as possible, but it is a target for us.
Your next question comes from the line of <unk> <unk> <unk>. Your line is open.
<unk>, so pure last quarter, you talked about say as a pure and the pickup we saw there. So as a pure has been sort of a slow and steady success. Since the Dupont days are you seeing that continue and if it is what is that say about the acceleration in demand coming this late.
Integral cycle.
Yeah, Mark you right Cyazypyr was launched later then Rynaxypyr. It is I would say it is somewhat more of a difficult sell as we've got our hands around the products, we understand that he'd have some attributes when it comes to the performance that also has planned health benefits in terms of how.
Responds to Cyazypyr and how Cyazypyr removes the past you know we talked about the size of our business in dynamites over over 2019, it's about a 1.6 billion dollar business.
Has upper is growing rapidly much faster than Rynaxypyr and is in the 352 400 million dollar range going forward. So it's already become a significant molecule. We don't believe at this point that its growth profile is slowing down certainly not in the near term. So you can expect us to talk more about.
Cyazypyr and especially the growth rates as we go forward.
Your next question comes from the line of Frank <unk> from Fermium Research airline is open.
A good morning, and congratulations mark on being named a C.E.O. elect I think and like and likewise peer a executive chair and I assume I'm, taking a little bit more time off but congratulations to you both up here.
He mentioned that over the past six months, you've been citing multiple new partnerships.
And I'm just curious if he could kinda describe them in a little more detail I mean, you know what are what products are these covering or these just covering the dye my geographic any any more color that you could expand upon is an end, perhaps just give us the sensors to you know what what size of your total revenues. You think this may this may grow too over the next couple of years.
Yeah.
Smile to jumping the only thing Franco was saying before Mark <unk> with most of these agreements. We do have we do have secrecy agreements. So we have very limited to what we consider on volume.
Actually being an annuity stage, you would be quite quite easy to to understand who is doing what so and and and as we said in the in the screen for a global agreement in 41, Oh local agreements all of them <unk> agreements Mark you want to say a few things in the car yeah, Yeah, Frank they.
The there's.
They cover both Rynaxypyr and Cyazypyr.
I see I said, we hour and a pretty tight confidentiality rules here, but suffice to say 11 different countries. So far all major crops and more importantly, some crops and markets that we are not acting today with the <unk>. So think of it in terms of.
Growth from a market access perspective in various countries around the world.
These are not products that are just straight straight rynaxypyr all cyazypyr. They are mixtures and sophisticated formulations with active ingredients that we don't have access to so the fundamental purpose here is not only to defend our franchise them grow it over the next decade, but also to expand the pool of where we operate.
I think about it this way the insecticide market is about a 15 billion dollar mark it.
A lot of the older chemistry is a going away and you know we have about $1.6 billion worth of business with the <unk>, we have plenty of room to grow here over the long haul and that is the purpose of what we're doing.
I think what would Mark say these are the n. is very important.
We we do believe those partner sheep are going to help us expanding the market penetration of says appear next happier those two molecules are big button, but we believe they'll fall from being at the end of them market penetration. So that's one of the which do each accomplishments.
All of the marketing in commercial activity if him she has barricade.
And your next question comes from the line of Laurent five with Exxon. Please go ahead.
It's good morning.
Get a question on the steps are indeed from 6.5% to 7% of sense.
If you could tennis, a little bit more about what's driving d. increases it and drink cost inflation and again you just in Cannes you could spending on this country, Yeah, I guess, new active you change in scope on formulations.
Oh is it just a bit of everything thank you.
Yeah, <unk> really the 40 million is targeted at two new active ingredients that we moved into development from discovery in 2019. So we now have that run right cost of spending money on what is really the most expensive part of the.
<unk>, R. and D. cycle, which is development.
We spend a lot of money on toxicology et cetera, So those products and now moving into a phase where for the next 345 years I'm spending will be increased 7% of revenue is not something that we see as a problem for us we actually have phased our r. and d.. So that we should be in that 7% range.
On an ongoing basis, you should expect to see that number change as we go through the years and the and the business continues to grow we will be spending more on r. and d. as we continue to expand not only the pipeline of synthetics biologicals as well.
Your next question comes from a line of Steve Burn from Bank of America line is open.
Yes, I was hoping you could comment on whether you're not you're seeing.
Any indications of some competitive pricing from any one of the following buckets one being the the crematoria the channel inventory levels, Mark that you mentioned in North America being higher than normal another potential one would be.
A big seed companies are increasingly bundling crop comes with their feed platforms.
Another one being.
Increase the commerce offerings anything that you're you're sitting there.
That would if you could comment on those please.
Thank you.
It's an first of all these you know each it's a highly competitive market. There is lots of companies in these markets were competing but at the end of the D. at the end of the D.V.D.'s enough market <unk> matter. So yes, there is <unk>.
But but at the end of the day, if you price ride the right technology you you can protect your your your managing.
Maybe mark let's let's start the comments about C. and the building and maybe talk about the meeting you and I, we had last week with the with the customers Yeah sure. So let's put it in perspective, you you're talking about seed bundling, you're really talking about major row crops in the mid west of the U.S.
And frankly, when you look at that as an overall component of our business. It's not it's not the majority of our business by a long way and even in the U.S., we have tremendous exposure outside of the Midwest.
We don't see the bundling aspect as a competitive threat to us.
The meeting P. I was referencing Pierre and I and the whole of the North America commercial team, we will with 250 retailers and distribution companies in the U.S. last week, and we spent three or four days talking about the market, where all we what's our complexity of offering and I can tell you no time did we here.
That the combination of seeds and chemicals is a detriment to outgrowth in fact, we had the opposite.
We had the fact that our offerings are offering technology on anybody seats. It doesn't matter, who seeds you buy can beat independent can be one of the big two or three so for US. We see this is an extreme positive unsold while retailers and so do our distribution partners. So in that sense no I don't see the the seeds combination is.
Being an issue for us.
The last bucket that you had Steve on E. Commerce, we actually see E. commerce as having a place in the marketplace, but frankly, we see it at the low end to the market, it's easy to sell a generic on price, it's not easy to sell a very sophisticated pre imagine how beside are very sophisticated dynamite insecticide online.
We don't participate in those forums, we will not participate in those forums. Our customers are the people that are offering the service levels down on the ground with the growers.
So for US, we're not seeing anything impacting our overall North America business through E. Commerce.
I want to I want you to repeat what Mark say because that is very critical and it is a strategic decision of S.N.C., we will not get into the C.D.'s and as we do not need to be into C. business when mark talked about 200 customers. It is true <unk>.
Spent most of the week I can tell you that to a person.
They told us that it's very pretty cool to have a chemical and biological should player who's agnostic to the type of seeds 10 somebody has the right technology. They can use we've any type of <unk>.
Customers and a big fans of burning or being pushed to use a specific seed was a specific can be cool they need the freedom to choose and and we provide that to them. So it is not something we are concerned about we do believe I wouldn't even go once they'd be on I think it's a competitive advantage for us to not being seats.
Your next question comes from the line of Mike <unk> well, it's vital your line is open.
Hey, guys nice end of the air and congrats to T. ball.
I think you mentioned the non die might the businesses <unk> mid single digits and 2020 can you maybe give us a little bit of color, where the gross coming from new molecules. You know geography is new registrations I'm sure. It's a little bit of all the above but just a little bit of come help their thanks.
Yeah, My <unk> it is a little bit of all the above as P.R. indicated our Oh legacy portfolio. We believe is growing in roughly the mixed single digits <unk> I would say across the board we've seen the highest growth rates with the funky side portfolio that we have spent a lot of time on growing that around the world mainly in North America.
Certainly the legacy a insecticide portfolio is doing extremely well, especially in Latin America, where we have some very very good products that are going into the soil complex.
And then we and then we would come to to the hobby size why we see grow up in in both the U.S. with some pretty sophisticated pre imagine formulations like authority edge that are replacing current technologies that are out there.
We see grow up in Argentina on pre imagines and we also see significant continued growth we've had besides since she was again in Brazil.
Moving over to Asia, India is a big market for is now and we're offering brand new hubby side formulations that have not been seen before in India, especially for sugar cane.
We continue to grow our rice herbicide business in China. So all those pieces that come together you can see it's quite easy for us to get into that mix made a single digit range.
Your next question comes from the line of Don <unk> <unk> financial airline is open.
Thank you want to go back to raw material costs and and your outlook for the year Pure you mentioned that you know that the higher class last year floats warming tray in the first half, but once you get through that.
Getting the second half to see raw material costs coming down.
And I know usually cashier supply chain, but is is availability out of China. A problem now that's crops grown with some of the reasons shutdowns could that have a second half effect on the industry.
Yes. So <unk> festival is when you started with the cost as we have forecasting a scene that are in there again.
You you are correct. The cost is turning into the signal and half of of the year into probably t., which means that.
Most of the <unk> cost you know P.N.L. is happening in the first half of the of the year, we as a disproportionate amount in the first quarter and then into C. one color. So and then when we get into into the show going ha that's when.
East Coast. These costs are are improving.
From a a new they availability stand point, where are we today.
<unk> you can get if the the issues, we had last year, which were due to environmental issues and.
Individual parts shutting down those those those issues are over a thing we are not suffering from any any issues day on the the thing well what she of course, he in fact of Corona virus.
There is no impact of Corona there is on demand to D. as we see it is much more an impact on logistics because of parts of the country, which are being isolated the roads, which are being blocked.
Oh, yeah freight today, we have not seen any negative impact.
On their ability to pay rates. So far we we had some issues, where we had to find options to get rule materials from a different location, but all you know the issues. We had been facing we have been able to resolve then it'll pay rates normally.
That being said as you can guess, it's a very done any situations shall we do have 18.
Really focused on that and only during the.
Day after day, which she's watching the flux of raw materials from a place to another to make sure. We do the we do have what we need for growth plan, but.
Yes. It is it is something we are we are aware of and and carefully watching but so far so far so good.
Necklines question comes from the line of my <unk>, Let's see park level. Your line is okay.
Hi, good morning.
The morning like.
Looking at the the one slide you have in their 13% growth in the Latin American crop protection market in 2019 that seems like a lot.
Where there really that many more planted acres or did we see increases of a number of applications was this trade benefits. Just just wondering if you can help us understand the drivers that very strong growth growth in the market itself.
And maybe get us more comfortable that we weren't just seeing a lot of inventory getting getting stuffed into the channel.
Yeah, and like I I listen I think is a very good observation I think most people when when we talk about 13% growth rate most people put that straight towards Brazil, I think you've got to pass laid out somewhat in the sense that.
You know the other regions are growing Mexico grew in the North and then obviously, Argentina has been growing suddenly for us, but the market was relatively I would say low single mic single digits. If you look at Brazil.
Surface area was planted was probably about a 3% increase overall with soil leading the way.
We had a very good season on canton strongly infestation, which obviously helped does but also the market was up because of that uncommon is a high usage of.
Of of pesticides, I would say, though that overall I think the mark It has more channel imagery in Brazil than the market would take so I think some of that 13% is is studying warehouses right now I'm going to be very Frank and tell you that you know we talk about this constantly on every call.
And our inventories are exactly where we want them to be normal levels across Brazil for the rest of this this season and then heading into the new season that comes in at the end of this year, but I do I do start to watch the channel inventories in Brazil, I think they are higher than normal.
And and to complement would mark stayed and there and the level of invention read the channel over him she products.
Just to.
Remind what we send the script growth was not Viva in the fourth quarter for efficiency by Brazil.
It was other parts of Latin America, and it'd be driver was Argentina. So that is part of the process. We have in place to make sure. They didn't breezy, we cultural generally inventory.
[noise]. Your next question comes from the line of Kevin Mccartney with Virtual Research partners. Your line is open.
Good morning, Thank you for taking my question.
Mark a question for you on insecticides as it relates to some of the regulatory dynamics with regard to core purifies, we understand that that chemistry is being phase out in California in Europe and so my question is whether F.M.C.
Foresees any opportunity to gain share by a substitute chemistries, such as <unk> or otherwise and then seconds. You mentioned the <unk> just wonder if you could address sat in terms of opportunity to backfill.
There what options she may have an a portfolio. Thank you.
Thanksgiving, Yeah, corporate <unk>, a molecule that is as you said being removed in California, we have very limited sales of closer a false around the world.
We have <unk> basically all of that business. So for us we see it as more of an opportunity and you're right <unk>, especially I'll buy censoring mixtures will be.
Targeting those market. So we'll be looking to grow that and then on top of your hand, yes, we do we do see opportunities for our portfolio to replace what we already have an an obviously if we were planning to x. It we had plans to replace and those plans will be rolled out in in Mexico.
Parts of Asia, Indonesia in particular, well, we will be replacing our own products with some of the some of the newer technologies.
Yeah. My clashing comes from the line of Joe Jackson from B.M.O. Capital Your line of open.
Good morning.
The job of bridging free cash flow conversion major pockets lacks a couple of years I just want to focus on the 19 versus 20 free cash flow conversion if working at the roughly $100 million are called percent conversion that is expected in 2020 instead of 19. It looks like you know normalized for everything twice.
<unk> 2020, Picasso conversion is actually less than 2019 conversion is that right and maybe you could have specifically walk through.
Some of that specifically walk through.
Actually the difference between 1920, if that's true.
Yeah.
Joel I think that that the free Casco conversion on a like for like is pretty consistent between the two years, what you've got us and puts and takes we have higher capital edition and higher legacy and transformations spending and 2020 and then we didn't 2019 to the tune is about $30 million.
<unk>.
We do see you know increased cash from operations.
Part of that as the you know recapture of the delayed collections that we saw the in the queue for and we also have to acknowledge we're we're growing the top on roughly 350 made 300 million dollar started me knowledge with it the Guy just point engineering $100 million. If you if it does take some working capital because.
Need to grow the business. So that yeah. When you think through that walk again, you know if we take 300 million and cast free cash flow and 2019 $100 million and gross and even 30 million dollar had went from higher legacy in transformation and capital spending that that get you out within 100 million of our guidance point <unk>.
And as the rebound you know that day reversal that queue for factors, we talked about and a very minimal change and working capital beyond that you know better than very mental use of working capital beyond that so it does imply containing improvements and working capital efficiency and that that's a part of our continued drive to derive and you're not just waiting for this.
Yep down the transformation spending but to continue to drive down the working capital usually.
Hi.
That's all the time, we have for the call today, Thank you and have a good day.
And this can close the F.M.C. Corporation conference call. Thank you.
We're sorry your conference is ending now please hang up.